CR9787A - Derivados de imidazopiridina como ligandos del receptor de canabinoides - Google Patents

Derivados de imidazopiridina como ligandos del receptor de canabinoides

Info

Publication number
CR9787A
CR9787A CR9787A CR9787A CR9787A CR 9787 A CR9787 A CR 9787A CR 9787 A CR9787 A CR 9787A CR 9787 A CR9787 A CR 9787A CR 9787 A CR9787 A CR 9787A
Authority
CR
Costa Rica
Prior art keywords
derivatives
imidazopiridine
canabinoid
ligands
receiver
Prior art date
Application number
CR9787A
Other languages
English (en)
Inventor
Andrew John Eatherton
Gerard Martin Paul Giblin
William Leonard Mitchell
Alan Naylor
Lee William Page
Martin Swarbrick
Jennifer Anne Sweeting
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516380A external-priority patent/GB0516380D0/en
Priority claimed from GB0524324A external-priority patent/GB0524324D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR9787A publication Critical patent/CR9787A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a nuevos derivados de imidazopiridina, a composiciones farmaceuticos que contienen estos compuestos y a su uso en el tratamiento de enfermedades, particularmente dolor, en donde dichas enfermedades estan provocadas directa o indirectamente por un aumento o disminucion en la actividad del receptor de cannabinoides.
CR9787A 2005-08-09 2008-02-29 Derivados de imidazopiridina como ligandos del receptor de canabinoides CR9787A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0516380A GB0516380D0 (en) 2005-08-09 2005-08-09 Compounds
GB0524324A GB0524324D0 (en) 2005-11-29 2005-11-29 Compounds

Publications (1)

Publication Number Publication Date
CR9787A true CR9787A (es) 2008-05-05

Family

ID=37192394

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9787A CR9787A (es) 2005-08-09 2008-02-29 Derivados de imidazopiridina como ligandos del receptor de canabinoides

Country Status (17)

Country Link
US (1) US20080221097A1 (es)
EP (1) EP1912985A1 (es)
JP (1) JP2009504587A (es)
KR (1) KR20080034457A (es)
AR (1) AR055601A1 (es)
AU (1) AU2006278191A1 (es)
BR (1) BRPI0614272A2 (es)
CA (1) CA2618165A1 (es)
CR (1) CR9787A (es)
EA (1) EA200800562A1 (es)
IL (1) IL188924A0 (es)
MA (1) MA29694B1 (es)
MX (1) MX2008001935A (es)
NO (1) NO20081195L (es)
PE (1) PE20070239A1 (es)
TW (1) TW200734335A (es)
WO (1) WO2007017237A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
AU2010231694A1 (en) 2009-03-30 2011-10-06 Astellas Pharma Inc. Pyrimidine compound
KR20130020881A (ko) 2010-02-08 2013-03-04 알러간, 인코포레이티드 칸나비노이드-2 효능제로서 유용한 피리다진 유도체
RS55186B1 (sr) * 2010-07-29 2017-01-31 Astellas Pharma Inc Kondenzovana jedinjenja piridina kao ligandi cb2 kanabinoidnog receptora

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113245B1 (en) * 1982-12-29 1989-03-15 Kureha Kagaku Kogyo Kabushiki Kaisha Cephalosporin derivatives
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6696448B2 (en) * 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
EP0931872B1 (de) * 1998-01-23 2003-04-09 Voith Paper Patent GmbH Verfahren zur Entfernung von feinen Verunreinigungen aus einer Faserstoffsuspension
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7332494B2 (en) * 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
US6369032B1 (en) * 2000-09-06 2002-04-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating allergies
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20060247261A1 (en) * 2002-08-21 2006-11-02 Eatherton Andrew J Pyrimidine compounds
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
WO2004074286A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
KR20070034049A (ko) * 2004-06-09 2007-03-27 글락소 그룹 리미티드 피롤로피리딘 유도체

Also Published As

Publication number Publication date
KR20080034457A (ko) 2008-04-21
NO20081195L (no) 2008-04-28
JP2009504587A (ja) 2009-02-05
MA29694B1 (fr) 2008-08-01
PE20070239A1 (es) 2007-04-01
AR055601A1 (es) 2007-08-29
MX2008001935A (es) 2008-03-26
CA2618165A1 (en) 2007-02-15
EP1912985A1 (en) 2008-04-23
US20080221097A1 (en) 2008-09-11
AU2006278191A1 (en) 2007-02-15
IL188924A0 (en) 2008-08-07
EA200800562A1 (ru) 2008-06-30
TW200734335A (en) 2007-09-16
BRPI0614272A2 (pt) 2011-03-22
WO2007017237A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
ECSP055613A (es) Derivados de pirimidina y su uso como moduladores cb2
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR9463A (es) Pirrolinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
CR20110270A (es) Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
UY32799A (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
ECSP099581A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
CO6612228A2 (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer
PA8623001A1 (es) Compuestos de quinolina sustituidos
PE20151892A1 (es) Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas
UY28945A1 (es) Derivados de pirrolopiridina
GT200500089A (es) Derivados de la 1-aminoftalazina, su preparacion y su uso terapeutico
CL2009000286A1 (es) Compuestos derivados de heterociclos espirociclicos sustituidos por eteres enlazados a quinazolina sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades pulmonares y de las vias respiratorias, enfermedad autoinmune, enfermedades alergicas y cancer, entre otras.
ECSP11011108A (es) Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
ECSP066991A (es) 3-(4-heteroarilciclohexilamino)ciclopentanocarboxamidas como moduladores de receptores de quimiocinas
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
CR9787A (es) Derivados de imidazopiridina como ligandos del receptor de canabinoides
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)